{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:12:56Z","timestamp":1784542376074,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Emory\/Georgia Tech Regenerative Engineering and Medicine Center"},{"name":"Aflac Cancer and Blood Disorders Center"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.bbmt.2015.01.014","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T12:40:30Z","timestamp":1422967230000},"page":"934-940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity"],"prefix":"10.1016","volume":"21","author":[{"given":"Ian B.","family":"Copland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-1996","authenticated-orcid":false,"given":"Jacques","family":"Galipeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.01.014_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1083-8791(00)70036-X","article-title":"A\u00a0randomized trial comparing prednisone with antithymocyte globulin\/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease","volume":"6","author":"Cragg","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.2174\/138161208785061436","article-title":"Novel drugs for the prevention and treatment of acute GVHD","volume":"14","author":"Cutler","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bbmt.2015.01.014_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2004-03-0854","article-title":"Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial","volume":"104","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.01.014_bib4","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/blood-2006-08-013995","article-title":"A\u00a0phase 2\/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease","volume":"109","author":"Macmillan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.01.014_bib5","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib6","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.leu.2403856","article-title":"Chronic graft-versus-host disease: where is promise for the future?","volume":"19","author":"Weisdorf","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.01.014_bib7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2174\/1566524011313050016","article-title":"Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation","volume":"13","author":"Stagg","year":"2013","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.bbmt.2015.01.014_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bbmt.2013.11.033","article-title":"Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients","volume":"20","author":"Introna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib9","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.01.014_bib10","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2015.01.014_bib11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2010.03.017","article-title":"Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population","volume":"16","author":"Lucchini","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","article-title":"Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease","volume":"81","author":"Ringden","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.01.014_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/bmt.2008.316","article-title":"Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium","volume":"43","author":"von Bonin","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jcyt.2012.10.002","article-title":"The mesenchymal stromal cells dilemma\u2014does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?","volume":"15","author":"Galipeau","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2015.01.014_bib15","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1182\/blood-2005-03-1004","article-title":"Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice","volume":"106","author":"Eliopoulos","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.01.014_bib16","doi-asserted-by":"crossref","first-page":"e87238","DOI":"10.1371\/journal.pone.0087238","article-title":"Allo-reactivity of mesenchymal stem cells in rhesus macaques is dose and haplotype dependent and limits durable cell engraftment in\u00a0vivo","volume":"9","author":"Isakova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2015.01.014_bib17","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2005-11-011650","article-title":"Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting","volume":"108","author":"Nauta","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.01.014_bib18","first-page":"557","article-title":"Ex\u00a0vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use","volume":"16","author":"Lazarus","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/14653240701851332","article-title":"Properties and potential of bone marrow mesenchymal stromal cells from children with hematologic diseases","volume":"10","author":"Dimitriou","year":"2008","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2015.01.014_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1089\/scd.2007.0008","article-title":"Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases","volume":"16","author":"Zhao","year":"2007","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.bbmt.2015.01.014_bib21","doi-asserted-by":"crossref","first-page":"e59756","DOI":"10.1371\/journal.pone.0059756","article-title":"Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells","volume":"8","author":"Andre","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2015.01.014_bib22","doi-asserted-by":"crossref","first-page":"7840","DOI":"10.1016\/j.biomaterials.2013.06.050","article-title":"The effect of platelet lysate fibrinogen on the functionality of MSCs in immunotherapy","volume":"34","author":"Copland","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbmt.2015.01.014_bib23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4049\/jimmunol.179.3.1549","article-title":"Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density","volume":"179","author":"Romieu-Mourez","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib24","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.4049\/jimmunol.0803864","article-title":"Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype","volume":"182","author":"Romieu-Mourez","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1520\/JFS2003045","article-title":"Allele frequencies for 15 autosomal STR loci on U.S. Caucasian, African American, and Hispanic populations","volume":"48","author":"Butler","year":"2003","journal-title":"J\u00a0Forensic Sci"},{"key":"10.1016\/j.bbmt.2015.01.014_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e3181938998","article-title":"Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used","volume":"87","author":"Bartsch","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.01.014_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.exphem.2005.02.004","article-title":"Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation","volume":"33","author":"Rieger","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1532\/IJH97.A10505","article-title":"Mesenchymal stem cells in stem cell transplant recipients are damaged and remain of host origin","volume":"82","author":"Wang","year":"2005","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.exphem.2006.03.007","article-title":"Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation","volume":"34","author":"Pozzi","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib30","first-page":"1421","article-title":"Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation","volume":"89","author":"Villaron","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.01.014_bib31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","article-title":"Immunological characterization of multipotent mesenchymal stromal cells\u2014The International Society for Cellular Therapy (ISCT) working proposal","volume":"15","author":"Krampera","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2015.01.014_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00262-014-1623-y","article-title":"Immune impairments in multiple myeloma bone marrow mesenchymal stromal cells","volume":"64","author":"Andre","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bbmt.2015.01.014_bib33","first-page":"310","article-title":"Effects of radiation on hematopoietic stroma","volume":"4","author":"Fried","year":"1976","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib34","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0301-472X(99)00076-4","article-title":"Stromal damage as consequence of high-dose chemo\/radiotherapy in bone marrow transplant recipients","volume":"27","author":"Galotto","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1203\/01.PDR.0000099773.71438.91","article-title":"Bone marrow stroma damage induced by chemotherapy for acute lymphoblastic leukemia in children","volume":"55","author":"Corazza","year":"2004","journal-title":"Pediatr Res"},{"key":"10.1016\/j.bbmt.2015.01.014_bib36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2004.05200.x","article-title":"Differential damage and recovery of human mesenchymal stem cells after exposure to chemotherapeutic agents","volume":"127","author":"Li","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib37","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/stem.139","article-title":"Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow","volume":"27","author":"Bieback","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbmt.2015.01.014_bib38","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jcyt.2013.05.020","article-title":"Human platelet lysate stimulates high-passage and senescent human multipotent mesenchymal stromal cell growth and rejuvenation in\u00a0vitro","volume":"15","author":"Griffiths","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbmt.2015.01.014_bib39","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00277-010-1141-8","article-title":"Alkylating chemotherapeutic agents cyclophosphamide and melphalan cause functional injury to human bone marrow-derived mesenchymal stem cells","volume":"90","author":"Kemp","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.canlet.2008.01.011","article-title":"Effects of adjuvant chemotherapy on bone marrow mesenchymal stem cells of colorectal cancer patients","volume":"263","author":"Cao","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bbmt.2015.01.014_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bmt.1701364","article-title":"Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells","volume":"22","author":"Schwartz","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/sj.bmt.1700916","article-title":"Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors","volume":"20","author":"Carlo-Stella","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.01.014_bib43","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.leu.2404466","article-title":"Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma","volume":"21","author":"Arnulf","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.01.014_bib44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.arcmed.2010.11.008","article-title":"Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients","volume":"41","author":"Li","year":"2010","journal-title":"Arch Med Res"},{"key":"10.1016\/j.bbmt.2015.01.014_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/mt.2011.189","article-title":"Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation","volume":"20","author":"Francois","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2015.01.014_bib46","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.exphem.2012.06.004","article-title":"Impact of lenalidomide on the functional properties of human mesenchymal stromal cells","volume":"40","author":"Wobus","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib47","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1002\/stem.1432","article-title":"Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages","volume":"31","author":"Melief","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbmt.2015.01.014_bib48","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/stem.1386","article-title":"Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation","volume":"31","author":"Jitschin","year":"2013","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbmt.2015.01.014_bib49","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/TP.0b013e3181ea4240","article-title":"Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT)","volume":"90","author":"Hoogduijn","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2015.01.014_bib50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4049\/jimmunol.1103705","article-title":"Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance","volume":"189","author":"Kheradmand","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2015.01.014_bib51","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.4049\/jimmunol.178.4.2212","article-title":"Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental\u00a0autoimmune encephalomyelitis","volume":"178","author":"Turley","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.bbmt.2015.01.014_bib52","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood-2014-02-555128","article-title":"Single dose of autologous apoptotic cells preceding transplantation significantly enhances survival in lethal murine graft versus host models","volume":"124","author":"Florek","year":"2014","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:57Z","timestamp":1761058317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1083879115000415"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.01.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Marrow Mesenchymal Stromal Cells from Patients with Acute and Chronic Graft-versus-Host Disease Deploy Normal Phenotype, Differentiation Plasticity, and Immune-Suppressive Activity","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}